Therapy Areas
Latest News
PharmaResearch to acquire CG USA to support North American expansion of REJURAN Cosmetics
1 July 2026 - South Korea-based regenerative medicine company PharmaResearch Co., Ltd. (KOSDAQ: 214450), which develops medicines, medical devices, cosmetics and health supplements, said on Wednesday it has agreed to acquire US cosmetics manufacturer...
Caris Life Sciences introduces Caris Detect multi-cancer early detection blood test
1 July 2026 - AI TechBio company Caris Life Sciences (NASDAQ: CAI) declared on Wednesday that it has launched Caris Detect, a multi-cancer early detection blood test designed to identify cancer signals at earlier and more treatable stages using ultra...
Cumberland Pharmaceuticals sharpens focus on rare disease pipeline with USD100m sale of branded US business to Apotex
1 July 2026 - US biopharmaceutical company Cumberland Pharmaceuticals Inc (Nasdaq: CPIX) announced on Wednesday that it has completed a USD100m transaction with Apotex, a subsidiary of Canadian-based pharmaceutical company Apotex Health Corp, under w...
Co-Diagnostics advances toward FDA filing after completing clinical validation for respiratory point-of-care test
1 July 2026 - Molecular diagnostics company Co-Diagnostics Inc (Nasdaq: CODX) disclosed on Monday that it has completed clinical and analytical performance studies supporting its planned FDA submission for the Co-Dx PCR Flu A/B & RSV upper respir...
SciBase submits FDA filing to expand Nevisense use to non‑melanoma skin cancers
1 July 2026 - Swedish medical technology company SciBase Holding AB (STO: SCIB), a developer of AI-based diagnostic solutions for skin disorders, announced on Wednesday that it has submitted a 510(k) premarket notification to the US Food and Drug Adm...
Biovica secures Japanese patent for immuno-oncology TKa application
1 July 2026 - Swedish biotech company Biovica International AB (FN STO:BIOVIC-B) announced on Wednesday that it has received a new patent from the Japanese Patent Office covering the use of TKa in relation to immune checkpoint inhibitor treatment in ...
Zelluna awarded NOK16m research grant for Phase 1 cancer study
30 June 2026 - Zelluna ASA (OSE:ZLNA), a Norway-based company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cells for the treatment of cancer, said on Tuesday that it has been awarded a NOK16m grant by ...